Senetek PLC December 16, 2008 Annual General Meeting Shareholder Presentation

Contract Categories: Business Operations › Proxy Agreements
Summary

This document is a presentation by Senetek PLC to its shareholders at the annual general meeting on December 16, 2008. It provides an overview of the company's business strategy, financial status, product pipeline, and market conditions. The presentation highlights Senetek's focus on dermatological therapeutics, recent product developments, financial performance, and adjustments in response to economic challenges. It also discusses shareholder-approved initiatives such as a share repurchase program. The document is intended to inform shareholders about the company's progress, outlook, and key business decisions.

View More
EX-10.1 2 dex101.htm DECEMBER 16, 2008 ANNUAL GENERAL MEETING SHAREHOLDER PRESENTATION December 16, 2008 Annual General Meeting Shareholder Presentation
ANNUAL GENERAL MEETING
December 16, 2008
Exhibit 10.1

SAFE HARBOR STATEMENT
This
contains
statements
that
may
be
considered
'forward-looking
statements'
within
the
meaning
of
the
Private
Securities
Litigation
Reform
Act.
Forward-
looking
statements
by
their
nature
involve
substantial
uncertainty,
and
actual
results
may
differ
materially
from
those
that
might
be
suggested
by
such
statements.
Important
factors
identified
by
the
Company
that
it
believes
could
result
in
such
material
differences
are
described
in
the
Company's
Annual
Report
on
Form
10-K
for
the
year
2007.
However,
the
Company
necessarily
can
give
no
assurance
that
it
has
identified
or
will
identify
all
of
the
factors
that
may
result
in
any
particular
forward-looking
statement
materially
differing
from
actual
results,
and
the
Company
assumes
no
obligation
to
correct
or
update
any
forward-looking
statements
which
may
prove
to
be
inaccurate,
whether
as
a
result
of
new
information,
future
events
or
otherwise.

•
World Class, Science Based Company Engaged in the Development of
Proprietary Technology Targeting the Science of Healthy Aging
•
Developers
and
Innovators
of
the
Leading
Selling
Anti-aging
Product
in
North
American
Physicians’
Offices,
Kinerase
™
•
Extensive Research Collaborations with Leading Institutions
•
Plethora of Proprietary Compounds with a Broad Range of Therapeutic
Applications
•
Three Commercial Contracts in Place (ED, Drug Delivery & Diagnostic MABs)
•
Financially Sound:  $16 Million in Cash ($2.08 per share) with Zero Debt
SENETEK PLC: AN OVERVIEW

•
Global Facial Skin Care:  A $20 Billion per Year Market
•
U.S. Facial Skin Care:  Estimated at $3 Billion per Year, CAGR of 7%
Source:  GCI
FOCUS ON SKIN CARE AND DERMATOLOGICAL
THERAPEUTICS

A STRATEGY FOR ENTRY
•
Achieve Validation of Science Through Product Endorsements by
Physician Thought Leaders
•
Initial Focus on the North American Physician Channel of Distribution
•
Pyratine-6
™
Maintains
High
Acceptance
with
Leading
Dermatologists
•
New
Pyratine-XR
™
to
be
Launched
at
the
Upcoming
American
Academy
of
Dermatology,
March
’09
•
2
nd
New Cytokinin
with
Differential Advantages Targeted for Launch to
the Physician Community in 2009

MAXIMIZING REVENUES
•
Establishing a Sales and Marketing InfraStructure
•
Expansion of Distribution Channels in North America
•
Seeking Licensing Partners for non-U.S.
•
Increasing Product Offerings
•
Seeking Out Merger and Acquisition Candidates

A PIPELINE OF INNOVATIVE TECHNOLOGIES
•
Kinetin & Zeatin:  Commercial Success
•
Invicorp
®
:
Licensed
to
Plethora
Holdings
Ltd.
For
North
America,
Targeted
U.S.
FDA
Approval
in
December
‘09;
Milestone
Payments
and
Double
Digit
Royalties
on
Net
Product
Sales
•
Reliaject
®
:
Sale
to
Ranbaxy
with
Milestone
Payments
and
Royalties
on
Net
Product
Sales
for
15
Years
from
the
Date
of
First
Commercial
Sale
•
Diagnostic Monoclonal Antibodies:  Licensed to Covance Representing a Cash
Revenue Stream
•
Pyratine-6
™
:
Launched
Selectively
to
Physicians
for
Photo
Aged
Skin
•
Pyratine-XR
™
:
To
Be
Launched
at
the
Upcoming
AAD,
March
‘09
for
Patients
Profiled
with
the
Signs
and
Symptoms
of
Rosacea

A PIPELINE OF INNOVATIVE TECHNOLOGIES
Continued
•
4HBAP:  Successfully Tested for Photo Damaged Skin with Unsurpassed
Efficacy in the Treatment of Coarse Wrinkles; To Be Studied for Acne Vulgaris
•
AK801:  Histological Mice Studies and Extended Cellular Culture Data Shows
Unsurpassed Biological Activity Related to a Myriad of Indications Such as
Photodamaged
Skin, Atopic
Dermatitis and Others.
•
PA100:  Non-Cytokinin
Derived from the Apple, Demonstrating Success for
Aiding Wound Healing
•
RNAi
Treatment Sequence for Glio
Blastoma, Successful Clinical Data in 46
Patients
•
50 Plus Compounds Successfully Screened for Biological Activity & No Toxicity

PYRATINE-6™
Baseline
Week 12

Baseline
Week 12
PYRATINE-XR™
Dr.
Jerry
McCullough,
lead
investigator
in
the
clinical
study
of
Pyratine-XR™
stated:
“In
addition
to
the
encouraging
results
in
the
treatment
of
photodamaged
skin
overall,
another
important
finding
is
the
significant
reduction
in
erythema
at
2
weeks
and
the
additional
reductions
at
weeks
4,
8
and
12.
To
my
knowledge,
this
is
the
first
report
to
show
reduced
erythema
associated
with
use
of
a
topical
non-prescription
therapeutic
product.”

4HBAP
Reduction in Coarse Wrinkles (L) and Acne Lesions (R)
Baseline
Week 12

PA FAMILY OF COMPOUNDS ENHANCES CELL MIGRATION
BY
3.8
TIMES
(380%)
IN
VITRO
control
PA
treated
Polycarbonate membranes showing 
migrated cells from two separate
experiments

PA FAMILY OF COMPOUNDS ARE A POTENTIAL
POWERFUL WOUND HEALER
•
Cell Migration and Collagen Contractions are Important Subprocesses During
Wound Healing
•
PA Family of Compounds Enhance Cell Migration by 3.8 Times In Vitro
•
PA Family of Compounds Contract Collagen Over the Controls by Over 100%
In Vitro
•
PA Family of Compounds Will be Extremely Useful for the Non-Healing
Impairments and Wound Healing in General
•
Marketing Keywords: Scratches, Bandage, Patches, Plastic Surgery, Diabetes
Cronic Wounds, Soother

FINANCIAL OVERVIEW:  “BUSINESS NOT AS USUAL”
•
Focus on Profit and Cash Conservation and Compilation
•
Recent Economic Downturn has Significantly Impacted Our Market
Place:
–
Aesthetic Medicine Office Visits are Down 20%
–
Major
Competitors
have
Terminated
Entire
Sales
Forces,
Thrown
in
the
Towel
or
Lowered
Projections
(Valeant
Pharma,
AGI
Dermatics,
OMP,
Artes
Medical,
etc.)
–
Lack of Available Financing is Slowing our Existing Commercial Partners
–
Potential Partners are Less Willing to Part with Cash
•
We have Slowed the Building of Our Sales & Marketing Organization
Directly Impacting Market Share/Projected Revenues

FINANCIAL OVERVIEW:  “BUSINESS NOT AS USUAL”
Continued
•
No Salary Increases or Bonuses for 2008
•
Reduced Financial Commitments, e.g., Consultants to be Placed Purely
on Fee for Project Basis
•
Complete Review of the Entire Organizational Structure
•
2009 Revenue Target Adjustment Downward to $9.6 Million with
Projected Break Even Profit and Operating Cash Flow
–
Skincare Projections Revised to Reflect Current Market Conditions and Competitive
Intelligence

OUR CAPITAL STRUCTURE
•
Proxy Proposal  Four on Share Repurchase Approved by Shareholders:
–
Perhaps a Wise and Judicious Time to Buy Back Shares
–
Accretive Ownership for Continued Shareholders
–
Potential to Pay Dividends Upon Achieving Significant Profits

SENETEK PLC:  IN SUMMARY
•
World Class Science
•
Strong Pipeline
•
Proven Commercial Successes
•
Cash on Hand
•
Debt Free
•
Dedicated Management Team

“THANK YOU FOR YOUR
CONTINUED SUPPORT”